文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

粪菌移植与胃肠道疾病患者多重耐药菌去定植:一项随机临床试验

Fecal Microbiota Transplant and Multidrug-Resistant Organism Decolonization in Gastrointestinal Disease: A Randomized Clinical Trial.
PubMed 文献 · JAMA Intern Med · 2026-01-01
一句话结论在胃肠道疾病合并持续多重耐药菌定植患者中,单次粪菌移植未显著提高4周去定植率或减少抗菌药物耐药基因。

该随机、双盲、假手术对照试验在印度一家三级医疗中心的消化科病房和重症监护室开展,纳入114例胃肠道疾病合并持续多重耐药菌定植患者,58例接受经结肠镜粪菌移植,56例接受假手术(乙状结肠镜生理盐水注射)。意向性分析显示,4周时多重耐药菌去定植率在粪菌移植组为31.0%(18例),假手术组为30.4%(17例),绝对差0.6%(95%CI -16.2%至17.6%,P=0.94),无显著差异;抗菌药物耐药基因中位数两组分别为2.5个和2.0个(P=0.68),不良事件相当。粪菌移植组在4至6周时观察到产短链脂肪酸细菌富集,病毒多样性未变,真菌组仅轻度短暂改变。结论认为单次粪菌移植未显著增强去定植或减少耐药基因,但调节了肠道微生物组多样性和组成。

要点

  • 在胃肠道疾病合并持续多重耐药菌定植患者中,单次经结肠镜粪菌移植4周去定植率为31.0%,假手术组为30.4%,绝对差0.6%(95%CI -16.2%至17.6%,P=0.94),无显著差异。
  • 抗菌药物耐药基因中位数粪菌移植组为2.5个(IQR 1.2-3.0),假手术组为2.0个(IQR 1.0-3.0),P=0.68,两组无显著差异。
  • 两组不良事件相当;粪菌移植组在4至6周时观察到产短链脂肪酸细菌富集,假手术组未观察到。
  • 粪菌移植后病毒多样性保持不变,真菌组仅出现轻度、短暂的改变。
  • 基线时多数患者定植碳青霉烯耐药肠杆菌目或超广谱β-内酰胺酶产生肠杆菌目(粪菌移植组55例[94.8%],假手术组56例[100%])。

适用人群与场景

  • 纳入:胃肠道疾病合并持续多重耐药菌定植的患者,来自印度一家三级医疗中心的消化科病房和重症监护室。
  • 基线特征:平均(SD)年龄40.6(12.5)岁;80例(70.2%)男性;52例(45.6%)胰腺炎;43例(37.7%)肝硬化;19例(16.7%)其他胃肠道疾病。

处置流程与药物剂量

  • 干预:粪菌移植通过结肠镜进行;对照为假手术(乙状结肠镜生理盐水注射)。
  • 单次粪菌移植,未报告具体菌液剂量、制备方法或疗程。

研究设计与关键结果

  • 研究类型:随机、双盲、假手术对照临床试验;样本量114例(粪菌移植组58例,假手术组56例);单中心(印度一家三级医疗中心);人群为胃肠道疾病合并持续多重耐药菌定植患者。
  • 主要终点:意向性分析显示4周多重耐药菌去定植率粪菌移植组18例(31.0%)vs 假手术组17例(30.4%),绝对差0.6%(95%CI -16.2%至17.6%),P=0.94,无显著差异。
  • 主要终点:抗菌药物耐药基因中位数粪菌移植组2.5个(IQR 1.2-3.0)vs 假手术组2.0个(IQR 1.0-3.0),P=0.68,无显著差异。
  • 次要终点:两组不良事件相当;粪菌移植组在4至6周时(71例接受16S rRNA基因测序的患者中)观察到产短链脂肪酸细菌富集,假手术组未观察到。
  • 次要终点:粪菌移植后病毒多样性保持不变;真菌组分析显示粪菌移植仅诱导轻度、短暂的肠道真菌组改变。
  • 失访:5例(粪菌移植组2例,假手术组3例)。

证据类型、等级与局限

  • 证据类型:随机、双盲、假手术对照临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,单次粪菌移植虽未显著增强胃肠道疾病患者的multiple耐药菌去定植或减少抗菌药物耐药基因,但调节了肠道微生物组多样性和组成。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Gut colonization by multidrug-resistant organisms (MDROs) is a risk factor for infection with these pathogens. There are no approved therapeutic interventions to combat it.

OBJECTIVE: To assess the efficacy of fecal microbiota transplant (FMT) in causing MDRO decolonization and decreasing antimicrobial resistance (AMR) genes and its impact on gut microbiome, virome, and mycobiome composition in patients with gastrointestinal (GI) diseases.

DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, sham-controlled clinical trial was conducted in a gastroenterology ward and intensive care unit at a tertiary care center in India. Participants were patients with GI diseases with persistent MDRO colonization. Patient recruitment occurred from July 2022 to June 2024, with follow-up completed in July 2024. Data were analyzed from October 1, 2024, to April 25, 2025.

INTERVENTION: FMT via colonoscopy or sham intervention (sigmoidoscopy with saline injection).

MAIN OUTCOMES AND MEASURES: Co-primary outcomes were MDRO decolonization rate and decrease in antimicrobial resistance genes (AMR) at 4 weeks after the intervention. Secondary outcomes included changes in stool microbiome (16S ribosomal RNA amplicon sequencing), virome (viruslike particles shotgun sequencing), and mycobiome (ITS2 sequencing); incidence of MDRO infections; and adverse events within 4 weeks.

RESULTS: Of 114 randomized patients (mean [SD] age, 40.6 [12.5] years; 80 [70.2%] male; 52 patients [45.6%] with pancreatitis; 43 patients [37.7%] with cirrhosis; 19 patients [16.7%] with other GI disorders), 58 received FMT and 56 received the sham intervention. Most patients were colonized with carbapenem-resistant Enterobacteriaceae or extended-spectrum β-lactamase-producing Enterobacteriaceae at baseline (55 patients [94.8%] in the FMT group and 56 patients [100%] in the sham group). Five patients (2 in the FMT group, 3 in the sham group) were lost to follow-up. Intention-to-treat analysis showed no significant differences in MDRO decolonization (18 patients [31.0%] in the FMT group vs 17 patients [30.4%] in the sham group; absolute difference, 0.6% [95% CI, -16.2% to 17.6%]; P = .94) or AMR genes (median [IQR], 2.5 [1.2 to 3.0] genes in the FMT group vs 2.0 [1.0 to 3.0] genes in the sham group; P = .68), with comparable adverse events. Among 71 patients who underwent 16S ribosomal RNA gene sequencing at 4 to 6 weeks after the intervention, enrichment of bacteria capable of producing short-chain fatty acids was observed in the FMT group. These microbial alterations were not observed in the sham group. However, viral diversity remained unchanged after FMT. Mycobiome analysis revealed that FMT induced only modest, transient alterations in the gut mycobiome.

CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that while a single session of FMT did not significantly enhance MDRO decolonization or decrease AMR genes in patients with GI diseases, it modulated gut microbiome diversity and composition.

TRIAL REGISTRATION: Clinical Trials Registry-India Registration No. 2022/07/043847.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Narang H, Talukdar D, Kumar B, et al. Fecal Microbiota Transplant and Multidrug-Resistant Organism Decolonization in Gastrointestinal Disease: A Randomized Clinical Trial. JAMA Intern Med. 2026. PMID: 42008253. doi:10.1001/jamainternmed.2026.0655

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。